Anticancer strategies that work with B-cell malignancies may not work so well with T-cell malignancies. Consider, for example, a strategy that involves wiping out both cancerous and noncancerous B cells. Although this strategy sounds extreme, it needn’t leave patients overly vulnerable to infections. Indeed, most patients can survive without B cells. That isn’t the case with T cells. If a treatment were to wipe out both normal and cancerous T cells, it would leave patients without a functioning ...